Ken Uchibori

1.2k total citations · 1 hit paper
59 papers, 885 citations indexed

About

Ken Uchibori is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Ken Uchibori has authored 59 papers receiving a total of 885 indexed citations (citations by other indexed papers that have themselves been cited), including 45 papers in Pulmonary and Respiratory Medicine, 38 papers in Oncology and 16 papers in Molecular Biology. Recurrent topics in Ken Uchibori's work include Lung Cancer Treatments and Mutations (40 papers), Lung Cancer Research Studies (17 papers) and Cancer Immunotherapy and Biomarkers (16 papers). Ken Uchibori is often cited by papers focused on Lung Cancer Treatments and Mutations (40 papers), Lung Cancer Research Studies (17 papers) and Cancer Immunotherapy and Biomarkers (16 papers). Ken Uchibori collaborates with scholars based in Japan, United States and Sweden. Ken Uchibori's co-authors include Ryohei Katayama, Naoya Fujita, Naohiko Inase, Yasushi Okuno, Mitsugu Araki, Mayumi Kamada, Shigeo Sato, Makoto Nishio, Noriko Yanagitani and Satoru Kitazono and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Ken Uchibori

54 papers receiving 876 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer

2017 329 citations Ken Uchibori, Naohiko Inase et al. Nature Communications profile →

Peers

Ken Uchibori

PRM

ONCOL

IMMUN

Francesca Casaluce Italy

Giuseppina Rosaria Rita Ricciardi Italy

Toshiki Takemoto Japan

Erin Larkins United States

Assunta Sgambato Italy

Joseph Chen United States

Shinnosuke Ikemura Japan

Jih‐Hsiang Lee Taiwan

Erina Hatashita Japan

G. Jeannin France

Francesca Casaluce Italy

Ken Uchibori

462 ×0.8

PRM

512 ×0.9

ONCOL

326 ×0.9

140 ×0.9

82 ×1.2

IMMUN

Citations per year, relative to Ken Uchibori Ken Uchibori (= 1×) peers Francesca Casaluce

Countries citing papers authored by Ken Uchibori

Since Specialization

Citations

This map shows the geographic impact of Ken Uchibori's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ken Uchibori with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ken Uchibori more than expected).

Fields of papers citing papers by Ken Uchibori

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ken Uchibori. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ken Uchibori. The network helps show where Ken Uchibori may publish in the future.

Co-authorship network of co-authors of Ken Uchibori

This figure shows the co-authorship network connecting the top 25 collaborators of Ken Uchibori. A scholar is included among the top collaborators of Ken Uchibori based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ken Uchibori. Ken Uchibori is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Seto, Yosuke, et al.. (2025). AXL‐Mediated Drug Resistance in ALK‐Rearranged NSCLC Enhanced by GAS6 From Macrophages and MMP11 Positive Fibroblasts. Cancer Science. 116(4). 1034–1047. 1 indexed citations

Furugaki, Koh, Satoshi Muraoka, Makoto Nishio, et al.. (2024). Targeting ErbB and tankyrase1/2 prevent the emergence of drug-tolerant persister cells in ALK-positive lung cancer. npj Precision Oncology. 8(1). 264–264. 4 indexed citations

Uchibori, Ken, et al.. (2024). Serum CYFRA 21-1 as a Prognostic Marker in Non-Small-Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors. Cancers. 16(21). 3712–3712. 1 indexed citations

Suzuki, Mai, Ken Uchibori, Tomoko Oh‐hara, et al.. (2024). A macrocyclic kinase inhibitor overcomes triple resistant mutations in EGFR-positive lung cancer. npj Precision Oncology. 8(1). 46–46. 5 indexed citations

Uchibori, Ken, Takahiro Akita, Ryo Ariyasu, et al.. (2024). Efficacy of osimertinib in patients with EGFR‐mutation positive non‐small cell lung cancer with malignant pleural effusion. Thoracic Cancer. 15(5). 402–409. 1 indexed citations

Akita, Takahiro, Ryo Ariyasu, Ken Uchibori, et al.. (2024). Distinction of ALK fusion gene‐ and EGFR mutation‐positive lung cancer with tumor markers. Thoracic Cancer. 15(10). 788–796. 2 indexed citations

Uchibori, Ken, Ai Takemoto, Sumie Koike, et al.. (2024). MIG6 loss increased RET inhibitor tolerant persister cells in RET-rearranged non-small cell lung cancer. Cancer Letters. 604. 217220–217220.

Ariyasu, Ryo, Takahiro Akita, Ken Uchibori, et al.. (2023). Real-World Outcome Analysis of Patients With Stage IV NSCLC Treated With Tyrosine Kinase and Immune Checkpoint Inhibitors. JTO Clinical and Research Reports. 4(6). 100524–100524. 4 indexed citations

Shimizu, Yuki, Ai Takemoto, Tomoko Oh‐hara, et al.. (2023). MIG6 loss confers resistance to ALK/ROS1 inhibitors in NSCLC through EGFR activation by low-dose EGF. JCI Insight. 8(24). 5 indexed citations

10.

Shimizu, Yuki, Koutaroh Okada, Jun Adachi, et al.. (2022). GSK3 inhibition circumvents and overcomes acquired lorlatinib resistance in ALK-rearranged non-small-cell lung cancer. npj Precision Oncology. 6(1). 16–16. 13 indexed citations

11.

Sakashita, Hiroyuki, Ken Uchibori, Toshiharu Tsutsui, et al.. (2022). A phase II feasibility study of carboplatin and nab‐paclitaxel for advanced non‐small cell lung cancer patients with interstitial lung disease (YLOG0114). Thoracic Cancer. 13(9). 1267–1275. 3 indexed citations

12.

Sakata, Seiji, Bo Gong, Yosuke Seto, et al.. (2021). Soluble PD-L1 works as a decoy in lung cancer immunotherapy via alternative polyadenylation. JCI Insight. 7(1). 37 indexed citations

13.

Yoshizawa, Takahiro, Ken Uchibori, Mitsugu Araki, et al.. (2021). Microsecond-timescale MD simulation of EGFR minor mutation predicts the structural flexibility of EGFR kinase core that reflects EGFR inhibitor sensitivity. npj Precision Oncology. 5(1). 32–32. 16 indexed citations

14.

Ariyasu, Ryo, Ken Uchibori, Takaaki Sasaki, et al.. (2021). Monitoring epidermal growth factor receptor C797S mutation in Japanese non–small cell lung cancer patients with serial cell‐free DNA evaluation using digital droplet PCR. Cancer Science. 112(6). 2371–2380. 8 indexed citations

15.

Seto, Yosuke, Koutaroh Okada, Ken Uchibori, et al.. (2020). Overcoming resistance by ALK compound mutation (I1171S + G1269A) after sequential treatment of multiple ALK inhibitors in non‐small cell lung cancer. Thoracic Cancer. 11(3). 581–587. 27 indexed citations

16.

Ariyasu, Ryo, Ken Uchibori, Hironori Ninomiya, et al.. (2020). Feasibility of next‐generation sequencing test for patients with advanced NSCLC in clinical practice. Thoracic Cancer. 12(4). 504–511. 15 indexed citations

17.

Yoshizawa, Takahiro, Ryo Ariyasu, Junji Koyama, et al.. (2019). Correlation between serum adenosine deaminase activity and efficacy of anti-programmed cell death-1 antibody. Lung Cancer. 133. 4–9. 5 indexed citations

18.

Uchibori, Ken, Naohiko Inase, Makoto Nishio, Naoya Fujita, & Ryohei Katayama. (2018). Identification of Mutation Accumulation as Resistance Mechanism Emerging in First-Line Osimertinib Treatment. Journal of Thoracic Oncology. 13(7). 915–925. 23 indexed citations

19.

Uchibori, Ken, Miyako Satouchi, Naoko Sueoka‐Aragane, et al.. (2018). Phase II trial of gefitinib plus pemetrexed after relapse using first-line gefitinib in patients with non-small cell lung cancer harboring EGFR gene mutations. Lung Cancer. 124. 65–70. 13 indexed citations

20.

Uchibori, Ken, Naohiko Inase, Mitsugu Araki, et al.. (2017). Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer. Nature Communications. 8(1). 14768–14768. 329 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact